Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Block Inc (XYZ) Price & Performance

Heron Therapeutics IncTrade
Block IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Block Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Block Inc trades at $80.52 (market cap $47.19B). The key difference: Block Inc is far larger — about 516× Heron Therapeutics Inc's market cap, and Block Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXXYZ
Market Cap
$91.46M$47.19B
Sector
HealthTechnology
52-Week High
$1.96$81.81
52-Week Low
$0.39$49.04
Enterprise Value
$189.36M$42.06B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Block Inc

Block (XYZ) trades at $79.72, down 0.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported mixed Q1 2026 earnings, beating expectations with $0.85 EPS versus $0.675 forecast, while revenue reached $24.19 billion in 2025. Recent news highlights include a $45 million settlement over Cash App fraud allegations and continued strength in Square and Cash App segments.

The stock offers 12% upside to the $89.53 consensus price target, supported by 74% analyst buy ratings. However, elevated P/E of 62.45 and declining net income margins from 12.01% to 5.39% pose valuation concerns. Key risks include rising credit losses and regulatory scrutiny, while AI integration and payment growth present long-term opportunities.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Block Inc

Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom

Read more on XYZ